Skip to content

Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome

Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome to Prevent Tracheal Intubation: the COVID-NIV Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04667923
Acronym
COVID-NIV
Enrollment
80
Registered
2020-12-16
Start date
2020-10-01
Completion date
2021-08-31
Last updated
2021-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, ARDS

Brief summary

Non-invasive ventilation can allow to avoid intubation and improve outcomes in moderate-to-severe COVID-19-associated acute respiratory distress-syndrome (ARDS). Data on NIV parameters adjustment based on expanded respiratory and gas exchange monitoring in COVID-19 associated ARDS is limited. Appropriate adjustment of the inspiratory positive airway pressure (IPAP) set as a point of the balance between minimal work of breathing (minimum point of W.Patrick scale for assessment of the accessory respiratory muscles and minimum diaphragm thickening fraction) and minimum tidal volume, and respiratory rate can decrease NIV failure in moderate-to-severe COVID-ARDS. The objective of the study is to evaluate the ability of non-invasive ventilation guided with expanded respiratory monitoring to decrease the intubation rate in in moderate-to-severe COVID-ARDS.

Detailed description

In December 2019, an outbreak of a novel coronavirus emerged in Wuhan, China and rapidly spread worldwide. The World Health Organization (WHO) declared the outbreak a pandemic on March 11th, 2020. The clinical disease (COVID-19) results in critical illness in about 5% of patients with predominant acute respiratory failure. The objective of the study is to evaluate the ability of non-invasive ventilation guided with expanded respiratory monitoring to decrease the intubation rate in in moderate-to-severe COVID-ARDS. Investigators will set IPAP as a point of the balance between minimal work of breathing (minimum point of W.Patrick scale for assessment of the accessory respiratory muscles, and minimum diaphragm thickening fraction) and minimum tidal volume, and respiratory rate. Investigators will set expiratory pressure at 8-10 cm of water and the inspiratory oxygen fraction (FiO2) to reach oxygen saturation by pulse oximetry (SpO2) 95%. All gas exchange measurements will be set at IPAP level. For gas exchange assessment investigators will measure partial oxygen tension in the arterial blood (PaO2), partial carbon dioxide tension in arterial blood (PaCO2), end-tidal carbon dioxide tension (PetCO2), then will calculate PAO2/FiO2, alveolar dead space (Vd alv) and ventilatory ratio (VR). Investigators will measure expiratory tidal volume (VT), respiratory rate (RR), peak inspiratory flow (PIF) and inspiratory time at 3 levels: at the set IPAP, at IPAP+4 cm of water and at IPAP-4 cm of water. Measurements will be repeated on day 1, 3, 5, 7, 14 and 21 of NIV. NIV failure is determined as one of the following at set IPAP 26 cm of water and FiO2 100%: fatigue, Patrick scale 5 points, SpO2\<92%, apnoea, hemodynamic instability or Glasgow coma score \<14 points. In patients with NIV failure after intubation and every 7 day after intubation investigators will measure plateau pressure and calculate the driving pressure at PEEP 8-10-12-14 cm of water and VT 6 ml/kg predicted body weight (PBW), and VT+100 ml and VT+200 ml at PEEP 8 cm of water, plot static pressure volume-curve at positive end-expiratory pressure (PEEP) 5 and 14 cm of water, and perform electro impedance tomography. This study is an observational trial in the ICU of the University hospital.

Interventions

DIAGNOSTIC_TESTRespiratory monitoring

Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation

DIAGNOSTIC_TESTRespiratory muscles ultrasound

Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles

DIAGNOSTIC_TESTElectro impedance tomography

Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants

DIAGNOSTIC_TESTCapnography

Measurement of end-tidal carbon dioxide tension

DIAGNOSTIC_TESTArterial blood gas

Measurement of the oxygen partial pressure and the carbon dioxide partial pressure

DIAGNOSTIC_TESTQuasistatic pressure-volume curve

Quasistatic pressure-volume curve

Sponsors

I.M. Sechenov First Moscow State Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* at least one of the following criteria: fatigue, Patrick scale 5 points, SpO2\<92% on standard oxygen therapy (\<15 l/min) or continuous positive airway pressure (CPAP)-therapy with oxygen flow\<15 l/min

Exclusion criteria

* pregnancy * age less than 18 or more than 80 years * life-threatening heart rhythm abnormalities and/or systolic blood pressure \< 80 mmHg despite norepinephrine at a dose \> 2 µg/kg/min * primary lung diseases (e.g. interstitial lung diseases, lung emphysema) or tumour metastases in lungs * chronic decompensated diseases with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure) * Glasgow cona score \< 14 * inability to swallow * upper airways obstruction

Design outcomes

Primary

MeasureTime frameDescription
Intubation rateOn day 28Frequency of NIV failure
MortalityOn day 28Mortality on day 28

Secondary

MeasureTime frameDescription
Change in alveolar dead spaceDays 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilationCalculation of the alveolar dead space using end-tidal carbon dioxide measurement and arterial carbon dioxide tension measurement
Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratioDays 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilationCalculation of the arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio using arterial oxygen tension measurement
Change in accessory respiratory muscles workloadDays 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilationCalculation of the Patrick's scale (minimum 0 points, maximum 5 points, more points means worse outcome)
Change in tidal volumeDays 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilationMeasurement of exhaled tidal volume
Change in ventilatory ratioDays 1, 3, 5, 7, 10, 14, 21 during noninvasive ventilationMeasurement of arterial carbon dioxide tension, minute ventilation and calculation of ventilatory ratio

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026